{"id":273,"date":"2026-04-24T19:36:05","date_gmt":"2026-04-24T19:36:05","guid":{"rendered":"https:\/\/asceticit.shop\/wp2\/?post_type=product&#038;p=273"},"modified":"2026-04-26T09:34:06","modified_gmt":"2026-04-26T09:34:06","slug":"nivorest-100","status":"publish","type":"product","link":"https:\/\/asceticit.shop\/wp2\/product\/nivorest-100\/","title":{"rendered":"Nivorest 100"},"content":{"rendered":"<p data-start=\"761\" data-end=\"1051\"><strong data-start=\"761\" data-end=\"785\">1. Product Overview:<\/strong><br data-start=\"785\" data-end=\"788\" \/>Nivorest\u00ae is an injectable formulation of Nivolumab, a monoclonal antibody used in immuno-oncology for the treatment of multiple advanced malignancies including non-small cell lung cancer, melanoma, renal cell carcinoma, Hodgkin lymphoma, and head &amp; neck cancers.<\/p>\n<p data-start=\"1053\" data-end=\"1157\"><strong data-start=\"1053\" data-end=\"1072\">2. Composition:<\/strong><br data-start=\"1072\" data-end=\"1075\" \/>Active Ingredient: Nivolumab | Dosage Form: Injection (Concentrate for Infusion)<\/p>\n<p data-start=\"1159\" data-end=\"1246\"><strong data-start=\"1159\" data-end=\"1188\">3. Pharmacological Class:<\/strong><br data-start=\"1188\" data-end=\"1191\" \/>Programmed Death-1 (PD-1) Immune Checkpoint Inhibitor<\/p>\n<p data-start=\"1248\" data-end=\"1493\"><strong data-start=\"1248\" data-end=\"1275\">4. Mechanism of Action:<\/strong><br data-start=\"1275\" data-end=\"1278\" \/>Nivolumab binds to the PD-1 receptor on T-cells, blocking its interaction with PD-L1\/PD-L2. This restores immune system activity against cancer cells, enabling the body to detect and destroy tumor cells effectively.<\/p>\n<p data-start=\"1495\" data-end=\"1676\"><strong data-start=\"1495\" data-end=\"1514\">5. Indications:<\/strong><br data-start=\"1514\" data-end=\"1517\" \/>Non-small cell lung cancer (NSCLC) | Melanoma | Renal cell carcinoma | Hodgkin lymphoma | Head and neck squamous cell carcinoma | Other advanced solid tumors<\/p>\n<p data-start=\"1678\" data-end=\"1880\"><strong data-start=\"1678\" data-end=\"1709\">6. Dosage &amp; Administration:<\/strong><br data-start=\"1709\" data-end=\"1712\" \/>As prescribed by oncologist | Intravenous infusion only | Administered in hospital or clinical setting | Dose and schedule depend on cancer type and patient condition<\/p>\n<p data-start=\"1882\" data-end=\"2085\"><strong data-start=\"1882\" data-end=\"1907\">7. Clinical Benefits:<\/strong><br data-start=\"1907\" data-end=\"1910\" \/>Enhances immune response against tumors | Improves overall survival in several cancers | Provides durable response in selected patients | Broad-spectrum immunotherapy option<\/p>\n<p data-start=\"2087\" data-end=\"2182\"><strong data-start=\"2087\" data-end=\"2112\">8. Contraindications:<\/strong><br data-start=\"2112\" data-end=\"2115\" \/>Hypersensitivity to Nivolumab or any component of the formulation<\/p>\n<p data-start=\"2184\" data-end=\"2387\"><strong data-start=\"2184\" data-end=\"2203\">9. Precautions:<\/strong><br data-start=\"2203\" data-end=\"2206\" \/>Risk of immune-related adverse effects (pneumonitis, colitis, hepatitis, endocrinopathies) | Requires regular monitoring of organ functions | Use under strict oncology supervision<\/p>\n<p data-start=\"2389\" data-end=\"2533\"><strong data-start=\"2389\" data-end=\"2415\">10. Drug Interactions:<\/strong><br data-start=\"2415\" data-end=\"2418\" \/>May interact with immunosuppressive drugs such as corticosteroids, potentially reducing therapeutic effectiveness<\/p>\n<p data-start=\"2535\" data-end=\"2713\"><strong data-start=\"2535\" data-end=\"2563\">11. Special Populations:<\/strong><br data-start=\"2563\" data-end=\"2566\" \/>Pregnancy: Not recommended | Lactation: Not recommended | Pediatric: Use only under specialist supervision | Elderly: Requires careful monitoring<\/p>\n<p data-start=\"2715\" data-end=\"2857\"><strong data-start=\"2715\" data-end=\"2739\">12. Adverse Effects:<\/strong><br data-start=\"2739\" data-end=\"2742\" \/>Fatigue | Skin rash | Diarrhea | Immune-related inflammation of lungs, liver, or intestines | Thyroid dysfunction<\/p>\n<p data-start=\"2859\" data-end=\"2991\"><strong data-start=\"2859\" data-end=\"2886\">13. Storage Conditions:<\/strong><br data-start=\"2886\" data-end=\"2889\" \/>Store at 2\u00b0C\u20138\u00b0C (refrigerated) | Do not freeze | Protect from light | Keep out of reach of children<\/p>\n<p data-start=\"2993\" data-end=\"3030\"><strong data-start=\"2993\" data-end=\"3011\">14. Packaging:<\/strong><br data-start=\"3011\" data-end=\"3014\" \/>Injection vial<\/p>\n<p data-start=\"3032\" data-end=\"3085\"><strong data-start=\"3032\" data-end=\"3053\">15. Manufacturer:<\/strong><br data-start=\"3053\" data-end=\"3056\" \/>Everest Pharmaceutical Ltd.<\/p>\n","protected":false},"excerpt":{"rendered":"<p data-start=\"151\" data-end=\"393\"><strong data-start=\"151\" data-end=\"168\">Generic Name:<\/strong> Nivolumab<br data-start=\"178\" data-end=\"181\" \/><strong data-start=\"181\" data-end=\"194\">Strength:<\/strong> 100 mg<br data-start=\"201\" data-end=\"204\" \/><strong data-start=\"204\" data-end=\"220\">Dosage Form:<\/strong> Injection (Concentrate for Infusion)<br data-start=\"257\" data-end=\"260\" \/><strong data-start=\"260\" data-end=\"273\">Category:<\/strong> Immuno-Oncology Therapy (Checkpoint Inhibitor)<br data-start=\"320\" data-end=\"323\" \/><strong data-start=\"323\" data-end=\"335\">TG Name:<\/strong> PD-1 Inhibitor<br data-start=\"350\" data-end=\"353\" \/><strong data-start=\"353\" data-end=\"364\">Status:<\/strong> Prescription Only Medicine<\/p>\n<hr data-start=\"395\" data-end=\"398\" \/>\n<h2 data-section-id=\"16ih8dt\" data-start=\"400\" data-end=\"426\"><span role=\"text\"><strong data-start=\"403\" data-end=\"424\">Short Description<\/strong><\/span><\/h2>\n<p data-start=\"427\" data-end=\"734\">Nivorest\u00ae 100 mg is an immunotherapy anticancer injection containing Nivolumab, used for the treatment of various advanced cancers such as lung cancer, melanoma, kidney cancer, and others. It works by activating the immune system to recognize and destroy cancer cells. To be used under oncology supervision.<\/p>\n","protected":false},"featured_media":335,"comment_status":"open","ping_status":"closed","template":"","meta":[],"product_brand":[],"product_cat":[23,30],"product_tag":[],"class_list":{"0":"post-273","1":"product","2":"type-product","3":"status-publish","4":"has-post-thumbnail","6":"product_cat-general-products","7":"product_cat-immunomodulators","9":"first","10":"instock","11":"shipping-taxable","12":"product-type-simple"},"_links":{"self":[{"href":"https:\/\/asceticit.shop\/wp2\/wp-json\/wp\/v2\/product\/273","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/asceticit.shop\/wp2\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/asceticit.shop\/wp2\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/asceticit.shop\/wp2\/wp-json\/wp\/v2\/comments?post=273"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/asceticit.shop\/wp2\/wp-json\/wp\/v2\/media\/335"}],"wp:attachment":[{"href":"https:\/\/asceticit.shop\/wp2\/wp-json\/wp\/v2\/media?parent=273"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/asceticit.shop\/wp2\/wp-json\/wp\/v2\/product_brand?post=273"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/asceticit.shop\/wp2\/wp-json\/wp\/v2\/product_cat?post=273"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/asceticit.shop\/wp2\/wp-json\/wp\/v2\/product_tag?post=273"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}